• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

7.940 +0.110 (+1.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,029,423
Open 7.810
Bid (Size) 7.910 (70)
Ask (Size) 8.150 (10)
Prev. Close 7.830
Today's Range 7.580 - 8.226
52wk Range 5.900 - 29.61
Shares Outstanding 73,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arvinas to Participate in Upcoming Investor Conferences
August 29, 2025
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
August 08, 2025
From Arvinas Inc.
Via GlobeNewswire

Performance

YTD
-58.0%
-58.0%
1 Month
+26.2%
+26.2%
3 Month
+1.4%
+1.4%
6 Month
-54.8%
-54.8%
1 Year
-68.4%
-68.4%

More News

Read More
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach
August 07, 2025
Via Stocktwits
Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates
August 06, 2025
Via Chartmill
Earnings Scheduled For August 6, 2025
August 06, 2025
Via Benzinga
What Analysts Are Saying About Arvinas Stock
June 02, 2025
Via Benzinga
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
July 30, 2025
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
July 09, 2025
From Arvinas Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm
June 23, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
June 18, 2025
Via Benzinga
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
June 13, 2025
From Arvinas Inc.
Via GlobeNewswire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
June 11, 2025
Via FinancialNewsMedia
Topics Artificial Intelligence
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
June 09, 2025
Via Benzinga
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
June 11, 2025
From FN Media Group LLC
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
June 06, 2025
From Pomerantz LLP
Via GlobeNewswire
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
June 06, 2025
Via Benzinga
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
June 06, 2025
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
June 05, 2025
From Arvinas Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
June 02, 2025
From Pomerantz LLP
Via GlobeNewswire
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 02, 2025
Via Benzinga
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
May 31, 2025
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Jefferies Global Healthcare Conference
May 30, 2025
From Arvinas Inc.
Via GlobeNewswire
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN)
May 28, 2025
From Kirby McInerney LLP
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
May 28, 2025
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Arvinas, Inc. - Common Stock publicly traded?
Yes, Arvinas, Inc. - Common Stock is publicly traded.
What exchange does Arvinas, Inc. - Common Stock trade on?
Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arvinas, Inc. - Common Stock?
The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market
What is the current price of Arvinas, Inc. - Common Stock?
The current price of Arvinas, Inc. - Common Stock is 7.940
When was Arvinas, Inc. - Common Stock last traded?
The last trade of Arvinas, Inc. - Common Stock was at 09/08/25 04:00 PM ET
What is the market capitalization of Arvinas, Inc. - Common Stock?
The market capitalization of Arvinas, Inc. - Common Stock is 581.21M
How many shares of Arvinas, Inc. - Common Stock are outstanding?
Arvinas, Inc. - Common Stock has 581M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap